Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protectin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Anthony T. P., Tang, Sydney C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Nephrology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731775/
https://www.ncbi.nlm.nih.gov/pubmed/35977903
http://dx.doi.org/10.23876/j.krcp.21.285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731775/
https://www.ncbi.nlm.nih.gov/pubmed/35977903
http://dx.doi.org/10.23876/j.krcp.21.285

Ejemplares similares